What does the evidence say about NAC Respiratory Infection Meta-Analysis?

The current Migaku evidence database contains 2 reusable source documents for NAC Respiratory Infection Meta-Analysis. This answer focuses on benefits, uncertainty, and practical interpretation. - This document consolidates existing evidence to this effect, and adds insights from practicing clinicians to guide about use of NAC in clinical practice. [Barne M (2026); evidence level 2] - Conclusion This consensus underscores the role of NAC in chronic respiratory diseases beyond its mucolytic properties and reiterates that NAC's antioxidant, anti-inflammatory, immunomodulatory and anti-biofilm properties provide significant clinical utility. [Barne M (2026); evidence level 2] - While promising for TB and respiratory infections, further evidence is required. [Barne M (2026); evidence level 2] - Background N-acetylcysteine (NAC) is a key precursor of glutathione (GSH), the lung's principal antioxidant. [Barne M (2026); evidence level 2] - Clinical evidence indicates that NAC and erdosteine can reduce exacerbation rates in COPD, carbocisteine shows benefit with prolonged administration, and dornase alfa remains a cornerstone in CF management. [Larobina D (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.